Phase II study of ONYX-015 in patients with hepatobiliary tumors with p53 correlative studies

被引：0
|
作者：
Wadler, S
Makower, D
Yu, B
Tan, JY
Rozenblit, A
Kaufman, H
Edelman, M
Lane, M
Zwiebel, J
Horwitz, M
机构：
[1] Cornell Univ, Weill Med Coll, Div Hematol Oncol, New York, NY USA
[2] Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA
[3] Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY USA
[4] Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10467 USA
[5] Albert Einstein Coll Med, Dept Surg, Bronx, NY 10467 USA
[6] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA
[7] Albert Einstein Coll Med, Dept Microbiol Immunol, Bronx, NY 10467 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
468
引用
收藏
页码：S140 / S141
页数：2
相关论文
共 50 条
  • [31] A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the baylor experience)
    Jeffery P. Lamont
    John Nemunaitis
    Joseph A. Kuhn
    Steven A. Landers
    Todd M. McCarty
    Annals of Surgical Oncology, 2000, 7 : 588 - 592
  • [32] A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)
    Lamont, JP
    Nemunaitis, J
    Kuhn, JA
    Landers, SA
    McCarty, TM
    ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (08) : 588 - 592
  • [33] A phase II trial of intratumoural injection with an E1B-deleted adenovirus, Onyx-015, in patients with recurrent refractory head and neck cancer
    Ganly, I
    Kirn, D
    Posner, M
    Vokes, E
    Nemunaitis, J
    Kaye, S
    HUMAN GENE THERAPY, 1999, 10 (05) : 844 - 844
  • [34] A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer
    Kaye, S
    Nemunaitis, J
    Ganly, I
    Posner, M
    Vokes, E
    Kuhn, J
    Heise, C
    Maack, C
    Kirn, D
    ANNALS OF ONCOLOGY, 1998, 9 : 22 - 22
  • [35] A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer
    Kaye, S
    Nemunaitis, J
    Ganly, I
    Posner, M
    Vokes, E
    Kuhn, J
    Heise, C
    Maack, C
    Kirn, D
    ANNALS OF ONCOLOGY, 1998, 9 : 86 - 86
  • [36] Onyx-015, an E1B deleted adenovirus, enhances the cytotoxicity to cisplatin and radiation in the functional p53 human ovarian adenocarcinoma cell line A2780
    Ganly, I
    Brown, R
    BRITISH JOURNAL OF CANCER, 1998, 78 : 19 - 19
  • [37] Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts
    Geoerger, B
    Grill, J
    Opolon, P
    Morizet, J
    Aubert, GV
    Terrier-Lacombe, MJ
    Bressac-de Paillerets, B
    Barrois, M
    Feunteun, J
    Kirn, DH
    Vassal, G
    CANCER RESEARCH, 2002, 62 (03) : 764 - 772
  • [38] Phase I/II study of intra-arterial administration of a replication-selective adenovirus CI-1042 (Onyx-015) in patients with metastatic colorectal carcinoma.
    Reid, T
    Galanis, E
    Abbruzzese, J
    Sze, D
    Andrews, J
    Randlev, B
    Romel, L
    Rubin, J
    Kirn, D
    CLINICAL CANCER RESEARCH, 2000, 6 : 4570S - 4570S
  • [39] A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
    Ganly, I
    Kirn, D
    Eckhardt, SG
    Rodriguez, GI
    Soutar, DS
    Otto, R
    Robertson, AG
    Park, O
    Gulley, ML
    Heise, C
    Von Hoff, DD
    Kaye, SB
    CLINICAL CANCER RESEARCH, 2000, 6 (03) : 798 - 806
  • [40] Phase I dose escalation trial of intravenous (IV) infusion of CI-1042 (ONYX-015) in patients with refractory cancer
    Nemunaitis, J
    Cunningham, C
    Uprichard, M
    Kim, D
    CANCER GENE THERAPY, 2000, 7 (12) : S8 - S8
12345